SIETES :: 93061 citas

Resultados de la búsqueda por RESULTADOS REFINAR BÚSQUEDA

1.

Dal-Ré R, Kesselheim AS, Bourgeois FT. Increasing access to FDA inspection reports on irregularities and misconduct in clinical trials. JAMA 2020:23 de abril. [Ref.ID 103599]

2.

Di Maio M, Audisio M, Cardone C, De Luca E, Gargiulo P, Zichi C, Perrone F. The use of not-negative conclusions to describe results of formally negative trials presented at oncology meetings. JAMA Oncology 2020:1. [Ref.ID 103598]

3.

DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet 2020;395:1 de febrero. [Ref.ID 103519]

4.

Khan MS, Lateef N, Siddiqi TJ, Rehmab KA, Alnaimat S, Khan SU, Riaz H, Murad H, Mandrola J, Doukky R, Krasuski RA. Level and prevalence of spin in published cardiovascular randomized clinical trial reports with statistically nonsignificant primary outcomes. A systematic review. JAMA Network Open 2019:3 de mayo. [Ref.ID 103114]

5.

Bafeta A, Koh M, Riveros C, Ravaud P. Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review. Ann Intern Med 2018;169:240-7. [Ref.ID 102815]

6.

Taichman DB, Backus J, Baethge C, De Leeuw PW, Drazen JM, Fletcher J, Frizelle FA, Groves T, Haileamlak A, James A, Laine C, Peiperl L, Sahni P, Wu S. Sharing clinical trial data — A proposal from the International Committee of Medical Journal Editors. N Engl J Med 2016;374:28 de enero. [Ref.ID 99977]

7.

Haukoos JS, Lewis RJ. The propensity score. JAMA 2015;314:1637-8. [Ref.ID 99568]

8.

Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 2015;385:2355-62. [Ref.ID 99290]

9.

Hughes DA, Pastores GM. Eliglustat for Gaucher's disease: trippingly on the tongue. Lancet 2015;385:2328-30. [Ref.ID 99287]

10.

Abraha I, Cherubini A, Cozzolino F, De Florio R, Luchetta ML, Rimland JM, Folletti I, Marchesi M, Germani A, Orso M, Eusebi P, Montedori A. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study. BMJ 2015;350:h2445. [Ref.ID 99147]

11.

Ebrahim S, Sohani ZN, Montoya L, Agarwal A, Thorlund K, Mills EJ, Ioannidis JPA. Reanalyses of randomized clinical trial data. JAMA 2014;312:1024-32. [Ref.ID 97952]

12.

Krumholz HM, Peterson ED. Open access to clinical trials data . JAMA 2014;312:1002-3. [Ref.ID 97950]

13.

Kmietowicz Z. Unpublished studies hold twice as much data on drugs as those in the public domain. BMJ 2013;347:5. [Ref.ID 96403]

14.

Hernán MA, Hernández-Díaz S, Robins JM. Randomized trials analyzed as observational studies. Ann Intern Med 2013;159:560-2. [Ref.ID 96385]

15.

Jones CW, Handler L, Crowel KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis.. BMJ 2013;347:1. [Ref.ID 96362]

16.

Anónimo. Making sense of equivalence and non-inferiority trials. Australian Prescriber 2013;36:170-3. [Ref.ID 96321]

17.

Saquib N, Saquib J, Ioannidis JPA. Practices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic study. BMJ 2013;347:15. [Ref.ID 96145]

18.

Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JPA. Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment. BMJ 2013;346:13. [Ref.ID 95374]

19.

Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med 2013;173:580-1. [Ref.ID 95262]

20.

Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, for the CONSORT PRO Group. Reporting on patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA 2013;309:814-22. [Ref.ID 94991]